BR112022025667A2 - Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a - Google Patents

Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a

Info

Publication number
BR112022025667A2
BR112022025667A2 BR112022025667A BR112022025667A BR112022025667A2 BR 112022025667 A2 BR112022025667 A2 BR 112022025667A2 BR 112022025667 A BR112022025667 A BR 112022025667A BR 112022025667 A BR112022025667 A BR 112022025667A BR 112022025667 A2 BR112022025667 A2 BR 112022025667A2
Authority
BR
Brazil
Prior art keywords
treatment
inflammatory bowel
bowel disease
induction
dosage regimen
Prior art date
Application number
BR112022025667A
Other languages
English (en)
Inventor
Lynn Baniecki Mary
Hassan-Zahraee Mina
Eugene Hung Kenneth
Li Gang
Xi Li
Ye Zhan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112022025667A2 publication Critical patent/BR112022025667A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

MÉTODOS DE TRATAMENTO DA DOENÇA INFLAMATÓRIA INTESTINAL COM ANTICORPOS TL1A. A presente invenção refere-se a um método para tratar a doença inflamatória intestinal (DII) em um paciente, o método compreendendo a administração ao paciente de um anticorpo de ligante semelhante a anti-TNF 1A (TL1A) em um regime de dosagem de indução suficiente para melhorar os sinais e sintomas de DII por pelo menos 12 semanas após o início do tratamento com o anticorpo anti-TL1A, o referido regime de dosagem de indução compreendendo uma pluralidade de doses de indução individuais, em que o método compreende também a administração ao paciente de um regime de dosagem de manutenção subsequente após a conclusão do regime de dosagem de indução, o referido regime de dosagem de manutenção compreendendo uma pluralidade de doses de manutenção individuais separadas umas das outras por pelo menos 2 semanas.
BR112022025667A 2020-06-26 2021-06-23 Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a BR112022025667A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063044390P 2020-06-26 2020-06-26
PCT/IB2021/055546 WO2021260577A2 (en) 2020-06-26 2021-06-23 Methods of treating inflammatory bowel disease with tl1a antibodies

Publications (1)

Publication Number Publication Date
BR112022025667A2 true BR112022025667A2 (pt) 2023-03-07

Family

ID=76730925

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025667A BR112022025667A2 (pt) 2020-06-26 2021-06-23 Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a

Country Status (9)

Country Link
US (1) US20230235070A1 (pt)
EP (1) EP4171632A2 (pt)
JP (1) JP2022022994A (pt)
KR (1) KR20230025898A (pt)
CN (1) CN116322762A (pt)
BR (1) BR112022025667A2 (pt)
CA (1) CA3187966A1 (pt)
MX (1) MX2022016590A (pt)
WO (1) WO2021260577A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
TW202346344A (zh) * 2022-01-07 2023-12-01 美商普羅米修斯生物科學股份有限公司 以tl1a抑制劑及il23抑制劑的組合治療發炎疾病之方法
WO2024026395A1 (en) 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
AU2006236508B2 (en) 2005-04-15 2012-02-02 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
EP3041580A4 (en) * 2013-09-06 2017-05-03 Cedars-Sinai Medical Center Systems, devices and methods for anti-tl1a therapy
CA3056647A1 (en) * 2013-11-13 2015-05-21 Robert ARCH Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
KR20230003433A (ko) * 2016-05-20 2023-01-05 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
MY191324A (en) * 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
MA52366A (fr) * 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés

Also Published As

Publication number Publication date
CN116322762A (zh) 2023-06-23
WO2021260577A3 (en) 2022-04-28
EP4171632A2 (en) 2023-05-03
MX2022016590A (es) 2023-02-01
WO2021260577A2 (en) 2021-12-30
US20230235070A1 (en) 2023-07-27
JP2022022994A (ja) 2022-02-07
CA3187966A1 (en) 2021-12-30
KR20230025898A (ko) 2023-02-23

Similar Documents

Publication Publication Date Title
BR112022025667A2 (pt) Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a
Li et al. Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota
Dong et al. Astragalus polysaccharides alleviates LPS‐induced inflammation via the NF‐κB/MAPK signaling pathway
Wang et al. Inhibition of activated astrocyte ameliorates lipopolysaccharide-induced depressive-like behaviors
Askarpour et al. Effect of bariatric surgery on serum inflammatory factors of obese patients: a systematic review and meta-analysis
Masoumi et al. Effect of combined use of calcium and vitamin B6 on premenstrual syndrome symptoms: a randomized clinical trial
BR112018015170A2 (pt) métodos para tratamento de doenças, para promoção de crescimento magro, para tratamento ou normalização de uma microbiota disbiótica no intestino, para aumentar riqueza gênica da microbiota intestinal, para aumentar número de filos da microbiota intestinal, para aumentar produção de ácidos graxos de cadeia curta da microbiota intestinal/metaboloma, para aumentar número de bactérias, para diminuir número de bactérias, defensina a, defensina ss, ou um fragmento bioativo das mesmas, e, defensina a e/ou defensina ss e/ou um glp-1/análogo de glp-1.
Coyle Symptom management and lifestyle modifications in multiple sclerosis
BR112018071683A2 (pt) método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
Bai et al. Intermittent caloric restriction with a modified fasting-mimicking diet ameliorates autoimmunity and promotes recovery in a mouse model of multiple sclerosis
Moludi et al. New insights on atherosclerosis: A cross-talk between endocannabinoid systems with gut microbiota
Bansal et al. A secondary bile acid from microbiota metabolism attenuates ileitis and bile acid reduction in subclinical necrotic enteritis in chickens
Xu et al. Brain-gut-liver axis: Chronic psychological stress promotes liver injury and fibrosis via gut in rats
BR112022004302A2 (pt) Anticorpos anti-il-27 e usos dos mesmos
Yoon et al. Endoscopic and percutaneous biliary interventions after liver transplantation: nationwide data in Korea
Audet Beyond the neuro-immune interplay in depression: Could gut microbes be the missing link?
Kalil et al. The association between preoperative chemotherapy and the prevalence of hepatic steatosis in hepatectomy for metastatic colorectal cancer
BR112022026533A2 (pt) Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
Yajnik Developmental origins of non-communicable diseases
Cox et al. Understanding ageing: biological and social perspectives
Li et al. Molecular mechanism by which the Notch signaling pathway regulates autophagy in a rat model of pulmonary fibrosis in pigeon breeder’s lung
CN110302214A (zh) 一种乳酸菌联合中链甘油三酯在修复肠道炎症中的应用
Shaughnessy Negative colonoscopy result predicts No colon cancer for more than 10 years
Rubin et al. A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, AN ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATE TO SEVERE ACTIVE, ANTI-TNFα AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS
Chen et al. Exploration of the Shared Gene and Molecular Mechanisms between Breast Cancer and Non-alcoholic Fatty Liver Disease Based on Available Public Transcriptome Sequencing Data

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PFIZER INC. (US)